Reshaping the narrative on biopharma innovation with BIO Board Chair Dr. Ted Love

Mainstage at the GA Life Sciences Summit

Dovetailing closely on access, advocacy, policy and innovation, BIO Board Chair and founder of Global Blood Therapeutics Dr. Ted Love discussed his mission oriented journey in the life sciences in the day’s keynote. This work continues with the need to reshape the narrative around biopharma innovation, access, cost and value.

“Drug cost is not a singular item,” Dr. Love told GRA Senior Advisor Greg Vaughn, MD in their post remarks chat. “We need to get copays out of the system and stop blocking egregious things we do to discourage patients from taking medicines.”

Our recent weekly bioBEAT summarized Dr. Love’s keynote thusly: 

“BIO Board Chair Dr. Ted Love founded a company (Global Blood Therapeutics—since acquired by Pfizer ) to develop treatments for sickle cell disease, so he is solidly grounded in the biopharma space. However, he’s enthusiastic about biotech’s potential to help achieve a wide range of societal goals. At Georgia Bio’s Life Sciences Summit this week, Ted spoke about the importance of communicating biotech’s full potential and opening minds to the promise of innovation.

“‘Showing the public how we change lives through innovations is a huge task that we must all embrace!’ he said in his remarks. ‘But, we can do this by telling everyone we talk to [that] biotechnology is our only hope – to fight egregious diseases and future pandemics, to produce clean energy to fight climate change, to solve food insecurity , and to provide biodefense to keep us all secure.’

“Ted shared a story about his own daughter’s (Alex) skepticism toward the biopharma industry—until she spent one summer working at Global Blood Therapeutics and saw firsthand how impactful the company’s work could be for patients. ‘Perhaps we can learn a lesson from my experience with Alex when it comes to reframing the narrative of our industry,’ he said.

“‘We need to increase awareness of what we are achieving in our society,’ he added, ‘by telling our powerful stories of innovation and standing up for science. It will require highlighting the possibilities of mRNA vaccines, gene therapy, crop editing , and the many other amazing technologies that we are investing in. mRNA took years and years to develop, but it arrived in time to treat Covid-19.’ Read Ted’s full remarks here.

Mainstage at the GA Life Sciences Summit
September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
MORE POSTS